Analysis 1.6. Comparison 1 Routine fetal movement counting versus mixed or undefined fetal movement counting, Outcome 6 Other fetal testing (cardiotocogram) on presentation with DFM rate per cluster (mean).. .. . Analysis 1.7. Comparison 1 Routine fetal movement counting versus mixed or undefined fetal movement counting, Outcome 7 Other fetal testing (cardiotocogram) on presentation with DFM.. .. .. .. .. .. . Analysis 1.8. Comparison 1 Routine fetal movement counting versus mixed or undefined fetal movement counting, Outcome 8 Other fetal testing (ultrasound) on presentation with DFM.

Background-Breast engorgement is a painful and unpleasant condition affecting large numbers of women in the early postpartum period. During a time when mothers are coping with the demands of a new baby it may be particularly distressing. Breast engorgement may inhibit the development of successful breastfeeding, lead to early breastfeeding cessation, and is associated with more serious illness, including breast infection.

Analysis 1.6. Comparison 1 Routine fetal movement counting versus mixed or undefined fetal movement counting, Outcome 6 Other fetal testing (cardiotocogram) on presentation with DFM rate per cluster (mean).. .. . Analysis 1.7. Comparison 1 Routine fetal movement counting versus mixed or undefined fetal movement counting, Outcome 7 Other fetal testing (cardiotocogram) on presentation with DFM.. .. .. .. .. .. . Analysis 1.8. Comparison 1 Routine fetal movement counting versus mixed or undefined fetal movement counting, Outcome 8 Other fetal testing (ultrasound) on presentation with DFM.

No abstract

BackgroundPostpartum haemorrhage remains an important cause of maternal death despite treatment with conventional therapy. Uncontrolled studies and one randomised comparison with conventional oxytocics have reported dramatic effects with high-dose misoprostol, usually given rectally, for treatment of postpartum haemorrhage, but this has not been evaluated in a placebo-controlled trial.MethodsThe study was conducted at East London Hospital Complex, Tembisa and Chris Hani Baragwanath Hospitals, South Africa. Routine active management of the third stage of labour was practised. Women with more than usual postpartum bleeding thought to be related to inadequate uterine contraction were invited to participate, and to sign informed consent. All routine treatment was given from a special 'Postpartum Haemorrhage Trolley'. In addition, participants who consented were enrolled by drawing the next in a series of randomised treatment packs containing either misoprostol 5 × 200 μg or similar placebo, which were given 1 orally, 2 sublingually and 2 rectally.ResultsWith misoprostol there was a trend to reduced blood loss ≥500 ml in 1 hour after enrolment measured in a flat plastic 'fracture bedpan', the primary outcome (6/117 vs 11/120, relative risk 0.56; 95% confidence interval 0.21 to 1.46). There was no difference in mean blood loss or haemoglobin level on day 1 after birth < 6 g/dl or blood transfusion. Side-effects were increased, namely shivering (63/116 vs 30/118; 2.14, 1.50 to 3.04) and pyrexia > 38.5°C (11/114 vs 2/118; 5.69, 1.29 to 25). In the misoprostol group 3 women underwent hysterectomy of whom 1 died, and there were 2 further maternal deaths.ConclusionsBecause of a lower than expected incidence of the primary outcome in the placebo group, the study was underpowered. We could not confirm the dramatic effect of misoprostol reported in several unblinded studies, but the results do not exclude a clinically important effect. Larger studies are needed to assess substantive outcomes and risks before misoprostol enters routine use.